stoxline Quote Chart Rank Option Currency Glossary
  
Sagimet Biosciences Inc. (SGMT)
4.1  0.04 (0.99%)    02-19 16:00
Open: 4.1
High: 4.21
Volume: 369,121
  
Pre. Close: 4.06
Low: 4.02
Market Cap: 126(M)
Technical analysis
2025-02-19 4:43:30 PM
Short term     
Mid term     
Targets 6-month :  5.5 1-year :  6.09
Resists First :  4.71 Second :  5.21
Pivot price 4.52
Supports First :  3.9 Second :  3.24
MAs MA(5) :  4.27 MA(20) :  4.45
MA(100) :  4.84 MA(250) :  4.42
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  14.2 D(3) :  23.5
RSI RSI(14): 41.7
52-week High :  7.63 Low :  2.39
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SGMT ] has closed above bottom band by 16.6%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.22 - 4.25 4.25 - 4.27
Low: 3.95 - 3.99 3.99 - 4.02
Close: 4.05 - 4.1 4.1 - 4.15
Company Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Headline News

Wed, 19 Feb 2025
Sagimet Biosciences Announces Oral Presentation at the MASH - GlobeNewswire

Sat, 01 Feb 2025
Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Mon, 27 Jan 2025
Jones Trading Initiates Coverage of Sagimet Biosciences (SGMT) with Buy Recommendation - Nasdaq

Mon, 13 Jan 2025
Sagimet Biosciences' SWOT analysis: promising NASH drug faces funding hurdles - Investing.com

Mon, 06 Jan 2025
Sagimet to Present Breakthrough MASH Treatment Data at MASH-TAG Conference 2025 - StockTitan

Mon, 16 Dec 2024
Sagimet Biosciences up 30% on strong clinical stage data - Mugglehead

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 31 (M)
Shares Float 18 (M)
Held by Insiders 14.6 (%)
Held by Institutions 58.3 (%)
Shares Short 5,180 (K)
Shares Short P.Month 4,160 (K)
Stock Financials
EPS -0.39
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.3
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -20.6 %
Return on Equity (ttm) -28 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -38 (M)
Levered Free Cash Flow -28 (M)
Stock Valuations
PE Ratio -10.52
PEG Ratio 0
Price to Book value 0.77
Price to Sales 0
Price to Cash Flow -3.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android